{"disease":{"id":"ischemic","name":"ischemic"},"drugs":{"marketed":[{"drug_id":"edoxaban","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"prasugrel","indication_name":"Prevention of recurrence of ischemic cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effient","generic_name":"PRASUGREL","company_name":"Cosette","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor","quality_score":80,"revenue":"400","mechanism":"Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"edaravone","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radicava","generic_name":"EDARAVONE","company_name":"Kk Bcj-94","drug_phase":"marketed","molecular_target":"","drug_class":"edaravone","quality_score":51,"revenue":null,"mechanism":"Radicava works by scavenging free radicals and reducing oxidative stress in the body."},{"drug_id":"butylphthalide","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"3-Butylphthalide","generic_name":"Butylphthalide","company_name":"CSPC Ouyi Pharmaceutical","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 2","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"heparin","indication_name":"Prevention of Ischemic Complications of Non-Q Wave MI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in non-Q-wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"no-oac","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Prevention of Transient Ischemic Attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"heparin-sodium","indication_name":"Prevention of Ischemic Complications of Non-Q Wave MI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"fendiline","indication_name":"Ischemic heart disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fendilin","generic_name":"FENDILINE","company_name":"","drug_phase":"phase_2","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"fendiline","quality_score":null,"revenue":null,"mechanism":"Fendiline works by binding to the extracellular calcium-sensing receptor, which helps regulate calcium levels in the body."},{"drug_id":"pf-07976016-formulation-a","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rosuvastatin","indication_name":"Prevention of Transient Ischemic Attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever 3D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP ProVue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter with Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave MI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"alteplase","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"radicava","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Radicava","company_name":"Shanghai Auzone Biological Technology Co., Ltd.","drug_phase":"marketed","molecular_target":"Polyunsaturated fatty acid lipoxygenase ALOX15","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"activase","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Activase","company_name":"Medical College of Wisconsin","drug_phase":"discontinued","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"plenaxis","indication_name":"Ischemic priapism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Plenaxis","company_name":"PRAECIS Pharmaceuticals Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"abarelix","indication_name":"Ischemic priapism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plenaxis","generic_name":"ABARELIX","company_name":"Speciality European","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"abarelix","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"antiplatelet-drug","indication_name":"Ischemic Stroke","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antiplatelet Drug","generic_name":"antiplatelet-drug","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"oral-anticoagulant","indication_name":"Cryptogenic ischemic stroke with patent foramen ovale (PFO)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":100,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07135310","title":"STROKE 120 ACTION Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1696000,"lead_sponsor_name":"Shanghai Minhang Central Hospital","has_results":false},{"nct_id":"NCT03939624","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","phase":"","overall_status":"COMPLETED","enrollment_count":419734,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03596502","title":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)","phase":"","overall_status":"COMPLETED","enrollment_count":402764,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT02550717","title":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","phase":"","overall_status":"COMPLETED","enrollment_count":398158,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04715594","title":"CONNECT DES Registrty","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04775836","title":"An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Ministry of Science and Technology of the People´s Republic of China","has_results":false},{"nct_id":"NCT06978348","title":"Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology.","phase":"","overall_status":"RECRUITING","enrollment_count":244296,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06098066","title":"Decoding Risks and Rewards in Ischemic Stroke Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":204411,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT05961748","title":"Registry of Multicenter Brain-Heart Comorbidity in China","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07052656","title":"Risk Factors and Outcomes in Patients Treated in Neurocritical Care","phase":"","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT06628817","title":"The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":55000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05779215","title":"Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT02795910","title":"Integrated Primary Care for Diabetes and Cardiovascular Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40577,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT07048717","title":"The Mauritius and Rodrigues Non-Communicable Disease (NCD) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39082,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT06001073","title":"Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06707987","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":23250,"lead_sponsor_name":"Supergene, LLC","has_results":false},{"nct_id":"NCT06933745","title":"Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":21029,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT03247036","title":"Long-Term Survival After Ischaemic Stroke: Ebrictus Study","phase":"","overall_status":"COMPLETED","enrollment_count":21000,"lead_sponsor_name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","has_results":false},{"nct_id":"NCT06613074","title":"Ali Pay Intelligent Navigation Applet-aided Pre-hospital Triage for Non-emergency Medical Service Patients With Acute Ischemic Stroke","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06077305","title":"A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04921397","title":"China Stroke Registry for Patients With Traditional Chinese Medicine","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Dongzhimen Hospital, Beijing","has_results":false},{"nct_id":"NCT06883383","title":"Data Analysis and Evaluation of the Incidence of Life-threatening Ventricular Arrhythmias in Patients with Newly Diagnosed Cardiomyopathies of NICM or MI/CAD Origin PROTECTED from SCD by a WCD","phase":"","overall_status":"COMPLETED","enrollment_count":19598,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06165107","title":"The Association Between Obesity-Related Indicators and Adverse Outcomes in Ischemic Stroke Patients","phase":"","overall_status":"COMPLETED","enrollment_count":18374,"lead_sponsor_name":"Qin Zhang","has_results":false},{"nct_id":"NCT03684629","title":"Computer Scan Based Analysing System on Improving Stroke Management Quality Evaluation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16570,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03578107","title":"Improve Acute Reperfusion Treatment Quality for Stroke in China, IMPROVE: Stroke Care in China","phase":"NA","overall_status":"COMPLETED","enrollment_count":15895,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04895462","title":"Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":15128,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT06763549","title":"COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15000,"lead_sponsor_name":"Peerbridge Health, Inc","has_results":false},{"nct_id":"NCT05702034","title":"A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07171242","title":"Shanghai Prospective Registry Study of Ischemic Stroke","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Qiang Dong","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT04972058","title":"Philippine Neurological Association One Database - Stroke","phase":"","overall_status":"COMPLETED","enrollment_count":14800,"lead_sponsor_name":"Philippine Neurological Association","has_results":false},{"nct_id":"NCT05686070","title":"A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12327,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04233515","title":"Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County","phase":"","overall_status":"COMPLETED","enrollment_count":11964,"lead_sponsor_name":"Region Örebro County","has_results":false},{"nct_id":"NCT02162017","title":"Head Position in Stroke Trial (HeadPoST)","phase":"NA","overall_status":"COMPLETED","enrollment_count":11096,"lead_sponsor_name":"The George Institute","has_results":false},{"nct_id":"NCT06904664","title":"An Application That Can Provide Early Warning of Temperature Health Risks and Give Protective Suggestions or Personalized Suggestions Based on Patients' Own Secondary Prevention Risk Factors Was Applied to Intervene, and the Intervention Effect of APP on Stroke Recurrence Risk Was Analyzed","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":10184,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03870815","title":"Long-term Outcomes and Prognostic Factors in Patient Undergoing CABG or PCI","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05864638","title":"Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT03079674","title":"China Registry of Non-disabling Ischemic Cerebrovascular Events","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03507517","title":"Quality Control Project of Stroke in Liaoning Province","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Hui-Sheng Chen","has_results":false},{"nct_id":"NCT07367893","title":"Exercise Echocardiography Registry for Ischemic and Non-Ischemic Heart Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03779217","title":"Breast Disease and Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT03380481","title":"SouthErn China REgisTry for Stroke on Traditional Chinese Medicine","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Yefeng Cai","has_results":false},{"nct_id":"NCT06422572","title":"Tissue Kallikrein Protect Against Ischemic Stroke","phase":"","overall_status":"COMPLETED","enrollment_count":8602,"lead_sponsor_name":"Qin Zhang","has_results":false},{"nct_id":"NCT05439356","title":"Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8343,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04916210","title":"Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06984211","title":"Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"HJN Sverige AB/Neko Health","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}